Project Grant P20AP00026

This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to develop and evaluate an evidence-based, behavioral cervical cancer screening intervention for women living with HIV in Ghana. The $511,959 award to Baylor University will fund a hybrid effectiveness-implementation trial to integrate and scale up a home-based HPV self-sampling and communication model intervention called HOPE. The project seeks to...

This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $260,250.00 to Health Research, Inc. at the Roswell Park Division to investigate "The Role of SLC45A3-ELK4 Chimera as a Molecular Determinant of Prostate Cancer Health Disparity." The award period runs from March 15, 2025 to March 14, 2027. The funding supports advanced biomedical research on cancer biology and therapeutic...

The National Cancer Institute (NCI) awarded a 5-year, $629,068 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to Albert Einstein College of Medicine to conduct an implementation study of integrated human papillomavirus (HPV) self-sampling in HIV care centers in Ethiopia. The study aims to leverage the Project ECHO (Extension for Community Healthcare Outcomes) virtual learning platform to promote experience sharing and technical assistance across 5 hospitals to improve...

This Project Grant from the Department of the Army Medical Command totaling $1,091,175 was awarded under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2021 for identification of novel biomarkers in African American prostate cancer. The awardee, Baylor College of Medicine, will complete the project by September 29, 2024. The grant supports research to identify actionable targets in African American prostate cancer in order to improve patient outcomes....

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...

This $215,546 Project Grant was awarded by the National Institute on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health (NIH), under the Minority Health and Health Disparities Research (CFDA 93.307) program. The project aims to evaluate the equity impact and cost-effectiveness of three real-world lung cancer screening strategies: the U.S. Preventive Services Task Force (USPSTF) guidelines, the American Cancer Society (ACS) guidelines, and a screening...

This Project Grant award from the Defense Health Agency provides $825,000 in funding to Fundacio Privada Institut D Investigacio Oncologica De Vall-Hebron for studying intratumor heterogeneity in the evolution of metastatic hormone-naive prostate cancer to castration resistance after intensified hormonal therapy. The award period runs from April 1, 2023 through May 31, 2027. The funding supports research under the Military Medical Research and Development program (CFDA 12.420), which aims to...

This federal Project Grant award for $4,036,820.00, granted by the National Institute on Minority Health and Health Disparities (NIMHD) under the Minority Health and Health Disparities Research (CFDA 93.307) program, will fund a 5-year multilevel peer-to-peer education program to increase Human Papilloma Virus (HPV) vaccinations and utilization of school-based health centers (SBHCs) among medically underserved adolescents. The primary awardee, Kaiser Foundation Hospitals, will develop tailored...

This Project Grant award from the Department of Defense's Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $564,000.00 to The Institute For Cancer Research, a subsidiary of Temple University, to increase clinical trial enrollment of underrepresented kidney cancer patients by improving access to participation. The award is for a two-year period from September 1, 2023 to August 31, 2025. The Institute For Cancer Research will leverage its...

The U.S. Defense Health Agency awarded a $1,056,000.00 Project Grant to the Beckman Research Institute of the City of Hope, a nonprofit organization, to conduct research on PP2A as a promising biomarker and therapeutic target in small cell lung cancer. The grant period runs from September 1, 2023 to August 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). The Beckman Research Institute, which has prior experience collaborating on federal health research...